Sardona Therapeutics is a preclinical biotechnology company building the leading platform to develop small molecule drugs that target RNA-binding proteins in the spliceosome and provide patients with therapy-resistant cancers novel, and potentially best-in-class, treatment options.

Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose. Backed by Foundation Fighting Blindness’s venture arm, the RD Fund, Opus combines unparalleled insight and commitment to patient need with wholly owned programs in numerous retinal diseases. Its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel manufacturing scale and efficiencies.

MyoKardia was acquired by BMS for $13.1 billion

MyoKardia is a biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. Lead compound mavacamten (CAMZYOS) approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in 2022.

Silk Road Medical is a medical device company that has pioneered a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR

Private equity firm focused on natural resources, infrastructure and real property investments. Actively involved in investments in American Midstream Partners (NYSE: AMID) and PetroPoint Energy Partners.

Analyst in the Energy Investment Banking group covering U.S. E&P, midstream/MLP and refining; transferred during second-year to the Mergers & Acquisitions group supporting a variety of industries.